Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 5, 2017. The document serves as a transaction notification regarding dealings in the company's ordinary shares by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them (PCAs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a disclosure of insider trading activity and does not contain financial performance data.
Material Changes and Transaction Details
The filing discloses five specific transactions involving GSK ordinary shares (ISIN: GB0009252882) executed on June 2, 2017:
- Mr. L. Debruyne (President, Global Vaccines): Sold 20,000 shares at £17.0177 on the London Stock Exchange.
- Mr. I. W. Whyte (PCA of Mrs. V. A. Whyte): Transferred 1,310 shares to his spouse for nil consideration.
- Mrs. V. A. Whyte (SVP & Company Secretary): Received 1,310 shares from her spouse for nil consideration.
- Mrs. V. A. Whyte (SVP & Company Secretary): Sold 9,215 shares at £17.07 on the London Stock Exchange.
- Mr. I. W. Whyte (PCA of Mrs. V. A. Whyte): Sold 4,690 shares at £17.07 on the London Stock Exchange.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to regulatory disclosure of share transactions.
Investor Verification Checklist
- Verify the total volume of shares sold by PDMRs on June 2, 2017 (33,905 shares sold).
- Confirm the transaction prices (£17.0177 and £17.07) against the market price on the London Stock Exchange for that date.
- Review the relationship between Mr. I. W. Whyte and Mrs. V. A. Whyte to understand the nil consideration transfer.
- Check subsequent filings for any changes in the shareholding percentages of the named executives.